검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | stem cells |
Overview Company | Genzyme, a Sanofi Company |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting the STAT3 pathway |
MoA Biomarker | biomarker changes following a single intrathecal injection of autologous bone marrow-derived mesenchymal stem |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.. Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeuti… |
Clinical PFS | 35.5 |
Clinical OS | 68 |
Clinical Result source | ClinicalTrials.gov NCT02208037 |
Clinical Data Tier / Score | A · 22 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | stem cells |
Overview Company | Genzyme, a Sanofi Company |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting the STAT3 pathway |
MoA Biomarker | biomarker changes following a single intrathecal injection of autologous bone marrow-derived mesenchymal stem |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.. Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeuti… |
Clinical PFS | 35.5 |
Clinical OS | 68 |
Clinical Result source | ClinicalTrials.gov NCT02208037 |
Clinical Data Tier / Score | A · 22 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교